Metastatic castrate-resistant prostate cancer: Dawn of a new age of management

BJU International

Volumn 110, Issue 8, 2012, Pages 1110-1114

  Masson, Susan ^a   Bahl, Amit ^a  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

chemotherapy; prostate cancer; urogenital malignancy

Indexed keywords

ABIRATERONE; CABAZITAXEL; CUSTIRSEN; DOCETAXEL; ENZALUTAMIDE; EPOTHILONE B; GRANULOCYTE COLONY STIMULATING FACTOR; IPILIMUMAB; IXABEPILONE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PLACEBO; PREDNISONE; SATRAPLATIN; SIPULEUCEL T; SUNITINIB; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAXOID;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; HYPOKALEMIA; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT REFERRAL; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; DRUG RESISTANCE; MALE; PATHOLOGY; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84871864476     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11076.x     Document Type: Review

References (29)

1. Cancer Research UK. Prostate cancer-UK incidence statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/. Accessed April 2012
2. Tannock IF, de Wit R, Berry WR, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
3. Berthold DR, Pond GR, de Wit R, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5
4. National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. Available at: http://www.nice.org.uk/nicemedia/live/ 11924/39687/39687.pdf. Accessed April 2012
5. Heidenreich A, Aus G, Bolla M, et al,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80
6. de Bono JS, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
7. de Bono JS, Logothetis CJ, Molina A, et al,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
8. Tran C, Ouk S, Clegg NJ, et al,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90
9. Kantoff PW, Higano CS, Shore ND, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
10. Slovin SF, Beer TM, Higano CS, et al,. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2009; 27: 15s (abstract 5138)
11. Department of Health. The National Cancer Survivorship Initiative vision. Available at: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/ @en/@ps/documents/digitalasset/dh-111477.pdf. Accessed April 2012
12. Sartor O,. Management of mHRPC patients previously treated with docetaxel-evidence of survival benefits. Industry Satellite symposium (sanofi aventis): beyond docetaxel-new treatment options in mHRPC. European Society of Medical Oncology Congress, Milan 2010
13. Dorff TB, Quinn DI,. Cabazitaxel in prostate cancer: stretching a string. Lancet 2010; 376: 1119-20
14. de Bono JS, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial (Supplementary webappendix). Lancet 2010; 376: 1147-54
15. Sanofi. Jevtana Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/24431/SPC/jevtana/. Accessed April 2012
16. Bissery M-C,. Preclinical evaluation of new taxoids. Curr Pharm Des 2001; 7: 1251-7
17. Pivot X, Koralewski P, Hidalgo JL, et al,. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19: 1547-52
18. Mita AC, Denis LJ, Rowinsky EK, et al,. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 723-30
19. Ansari J, Hussain SA, Zarkar A, et al,. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008; 20: 891-6
20. Sternberg CN, Petrylak DP, Sartor O, et al,. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8
21. Rosenberg JE, Weinberg VK, Kelly WK, et al,. Activity of second-line chemotherapy in docetaxel refractory hormone refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 556-63
22. Beardsley E, Saad F, Venner F, Winquist Y,. A phase II study of patupilone in patients (pts) with metastatic castrate-resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol 2009; 27: 15s (abstract 5139)
23. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308
24. Johnson DE, Babaian RJ, von Eschenbach AC, et al,. Ketoconazole therapy for hormonally refractive metastatic prostate cancer. Urology 1988; 31: 132-4
25. Small EJ, Baron AD, Fippin L, Apodaca D,. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157: 1204-7
26. Chi KN, Zoubeidi A, Gleave ME,. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs 2008; 17: 1955-62
27. Sonpavde G, Periman PO, Bernold D, et al,. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 319-24
28. Fong PC, Boss DS, Yap TA, et al,. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34
29. Malik ZI,. Cabazitaxel: evidence and clinical experience. Br J Med Surg Urol 2011; 4: S14-S20